» Articles » PMID: 35677514

Diagnostic Accuracy and Optimal Cut-off of Controlled Attenuation Parameter for the Detection of Hepatic Steatosis in Indian Population

Overview
Publisher Elsevier
Specialty Gastroenterology
Date 2022 Jun 9
PMID 35677514
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: Ultrasound of the liver is not good to pick up mild steatosis. Controlled attenuation parameter (CAP) evaluated in transient elastography (FibroScan) is widely available in India. However, data regarding the diagnostic accuracy and optimal cut-off values of CAP for diagnosing hepatic steatosis are scarce in Indian population. MRI-PDFF is an accurate technique for quantifying hepatic steatosis. Thus, this study examined the diagnostic accuracy and optimal cut-off values of CAP for diagnosing steatosis with MRI-PDFF as reference standard.

Methods: A total of 137 adults underwent CAP and MRI-PDFF measurements prospectively. A subset of participants (n = 23) underwent liver biopsy as part of liver transplantation evaluation. The optimal cut-off values, area under the receiver operating characteristic (AUROC) curves, sensitivity, and specificity for CAP in detecting MRI-PDFF ≥5% and ≥10% were assessed.

Results: The mean age and body mass index (BMI) were 44.2 ±10.4 years and 28.3 ±3.9 kg/m, respectively. The mean hepatic steatosis was 13.0 ±7.7% by MRI-PDFF and 303 ±54 dB/m by CAP. The AUROC of CAP for detecting hepatic steatosis (MRI-PDFF ≥5%) was 0.93 (95% CI, 0.88-0.98) at the cut-off of 262 dB/m, and of MRI-PDFF ≥10% was 0.89 (95% CI, 0.84-0.94) at the cut-off of 295 dB/m. The CAP of 262 dB/m had 90% sensitivity and 91% specificity for detecting MRI-PDFF ≥5%, while the CAP of 295 dB/m had 86% sensitivity and 77% specificity for detecting MRI-PDFF ≥10%.

Conclusions: The optimal cut-off of CAP for the presence of liver steatosis (MRI-PDFF ≥5%) was 262 dB/m in Indian individuals. This CAP cut-off was associated with good sensitivity and specificity to pick up mild steatosis.

Citing Articles

Accuracy of Controlled Attenuation Parameter for Liver Steatosis in High-Risk Patients for MASLD Using MRI-Proton Density Fat Fraction as Reference Standard.

Malandris K, Korakas E, Sarakapina A, Kalopitas G, Iatridi F, Liakos A Dig Dis Sci. 2024; 70(2):814-824.

PMID: 39708259 DOI: 10.1007/s10620-024-08799-7.


Accuracy of controlled attenuation parameter for liver steatosis in patients at risk for metabolic dysfunction-associated steatotic liver disease using magnetic resonance imaging: a systematic review and meta-analysis.

Malandris K, Katsoula A, Liakos A, Bekiari E, Karagiannis T, Theocharidou E Ann Gastroenterol. 2024; 37(5):579-587.

PMID: 39238800 PMC: 11372538. DOI: 10.20524/aog.2024.0910.


Non-invasive hepatic fat quantification: Can multi-echo Dixon help?.

Gupta A, Dixit R, Prakash A Radiol Bras. 2024; 57:e20230125.

PMID: 38993969 PMC: 11235074. DOI: 10.1590/0100-3984.2023.0125.


A Novel Score Based on Controlled Attenuation Parameter Accurately Predicts Hepatic Steatosis in Individuals With Metabolic Dysfunction Associated Steatotic Liver Disease: A Derivation and Independent Validation Study.

An Z, Liu Q, Ye X, Zhang Q, Pei H, Xin X Clin Transl Gastroenterol. 2024; 15(3):e00680.

PMID: 38240390 PMC: 10962889. DOI: 10.14309/ctg.0000000000000680.


First-in-human diagnostic study of hepatic steatosis with computed ultrasound tomography in echo mode.

Stahli P, Becchetti C, Korta Martiartu N, Berzigotti A, Frenz M, Jaeger M Commun Med (Lond). 2023; 3(1):176.

PMID: 38071269 PMC: 10710459. DOI: 10.1038/s43856-023-00409-3.


References
1.
Singh S, Allen A, Wang Z, Prokop L, Murad M, Loomba R . Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2014; 13(4):643-54.e1-9. PMC: 4208976. DOI: 10.1016/j.cgh.2014.04.014. View

2.
Permutt Z, Le T, Peterson M, Seki E, Brenner D, Sirlin C . Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther. 2012; 36(1):22-9. PMC: 3437221. DOI: 10.1111/j.1365-2036.2012.05121.x. View

3.
Kuchay M, Choudhary N, Mishra S, Bano T, Gagneja S, Mathew A . Prevalence of clinically relevant liver fibrosis due to nonalcoholic fatty liver disease in Indian individuals with type 2 diabetes. JGH Open. 2021; 5(8):915-922. PMC: 8341185. DOI: 10.1002/jgh3.12606. View

4.
Kuchay M, Krishan S, Mishra S, Choudhary N, Singh M, Wasir J . Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Diabetologia. 2020; 63(11):2434-2445. DOI: 10.1007/s00125-020-05265-7. View

5.
Choudhary N, Saraf N, Saigal S, Duseja A, Gautam D, Rastogi A . Nonalcoholic Fatty Liver in Lean Individuals: Clinicobiochemical Correlates of Histopathology in 157 Liver Biopsies from Healthy Liver Donors. J Clin Exp Hepatol. 2021; 11(5):544-549. PMC: 8414316. DOI: 10.1016/j.jceh.2021.01.004. View